Morgan Stanley lowered the firm’s price target on GoodRx (GDRX) to $4 from $5 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Approves Retention Bonuses for CEO and CFO
- GoodRx initiated with an Underweight at Barclays
- GoodRx price target lowered to $3 from $3.40 at BofA
- GoodRx announces weight loss telemedicine subscription, Novo Nordisk pact
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month